Research report
A research report is the sourced material a domain
dossier is synthesized from — generated on a plan and a cadence, one topic per file.
A report carries no confidence tags. Its bracketed markers say who might have
an incentive to shade a line; none of them says anyone checked it. To reach a score, a line has
to be drafted onto a candidate as unverified and pass the Verifier or the
Corroborator, like everything else.
Section reference-products · Version 2026-09-30 · Cadence quarterly · Evidence class mixed · Sources 21 · Supersedes none
Domain: stress-urinary-incontinence · Scope: Public primary sources reachable by this repo's connectors, WebSearch and WebFetch — CMS (Centers for Medicare & Medicaid Services) National and Local Coverage Determinations read on the Medicare Coverage Database, a DME MAC (durable medical equipment Medicare administrative contractor) article, eCFR and openFDA classification via connectors, and PubMed abstracts via connectors. Excludes CPT (Current Procedural Terminology) descriptors (AMA-licensed), fda.gov guidance, case law and Medicare Appeals Council decisions (one fetch refused), commercial payer policies, full texts behind paywalls, and jurisdictions other than US.
Sourcing: Coverage text rests on CMS NCD (national coverage determination)/LCD documents read directly; what happened rests on single observational studies per case, mostly abstracts, with no study anywhere that isolates the effect of a documented-failed-trial requirement on prescribing volume.
Medicare has required a documented failed conservative trial before covering a home or adjunct device in at least three device categories: non-implantable pelvic floor electrical stimulators and biofeedback for urinary incontinence (4 weeks of ordered pelvic muscle exercise) [1][2], and pneumatic compression devices for lymphedema (4 weeks of compression, exercise and elevation) [12]. CPAP carries the mirror-image requirement — documented adherence and an in-person re-evaluation between day 31 and day 91 to keep coverage [7]. The pelvic floor precedent already exists for exactly the device class at issue: FDA (US Food and Drug Administration) product code KPI is a Class II (FDA device class II) non-implanted electrical continence device under 21 CFR (Title 21 of the Code of Federal Regulations) 876.5320 [3][4]. No retrieved study measures what the documented-trial requirement itself did to prescribing volume in any of these categories; what is published measures adherence against the coverage threshold (CPAP), treatment gaps (lymphedema), uptake of the conservative step (pelvic floor PT (physical therapist)), and documentation workflow and supplier contraction (power mobility).
_Baseline (v1). No prior version; this establishes the starting point for future diffs._
Had to show: NCD 230.8 (a Medicare national coverage determination number) covers a non-implantable pelvic floor stimulator for stress and/or urge incontinence "in cognitively intact patients who have failed a documented trial of pelvic muscle exercise (PME) training", a failed trial being "no clinically significant improvement in urinary continence after completing 4 weeks of an ordered plan of pelvic muscle exercises" (version 2, effective 2006-06-19) [1] [single-source]. NCD 30.1.1 applies the same 4-week definition to biofeedback, and states "Home use of biofeedback therapy is not covered" (effective 2001-07-01) [2] [single-source]. The device class is KPI, "Stimulator, Electrical, Non-Implantable, For Incontinence", Class II, 21 CFR 876.5320 [3][4].
What happened: No retrieved study reports prescribing volume, prescriber specialty, or denial rates for home pelvic floor stimulators under NCD 230.8. What is measured is uptake of the conservative step itself: among women referred to pelvic floor PT for urinary incontinence (cross-sectional telephone survey, January 2009–June 2010), 33% with private insurance and 17% with other insurance did not participate; insurance noncoverage (OR 103.85) and negative perception of benefit (OR 5.07) were risk factors, and Medicare was protective [5] [single-source]. In a 5% Medicare sample of 33,010 women with fecal incontinence (2010–2018), 9.6% received any treatment and 0.1% received pelvic floor PT with biofeedback [6] [single-source]. A 2002 review records that the 2000 national coverage decision followed organised advocacy by a nursing continence coalition, "there was a real threat that coverage could be withdrawn" [17] [single-source].
Transfers: Same condition, same device class (KPI), same prerequisite (4 weeks of ordered PME), same payer; the documented trial is typically delivered by pelvic floor PT or in-office biofeedback — the office-based care the experiment asks prescribers to move away from.
Does not transfer: The NCD defines "failure" as no clinically significant improvement, not a scored threshold; biofeedback is excluded from home coverage outright, so a home EMG (electromyography) biofeedback device does not inherit the stimulator's pathway; the PT-uptake figures come from one referral cohort and the treatment figure from fecal, not urinary, incontinence.
Had to show: Adherence "defined as use of PAP ≥4 hours per night on 70% of nights during a consecutive thirty (30) day period anytime during the first three (3) months", plus an in-person clinical re-evaluation between day 31 and day 91; otherwise "continued coverage of a PAP device and related accessories will be denied as not reasonable and necessary" (revision effective 2024-01-01) [7] [single-source].
What happened: In manufacturer telemonitoring data on 789,260 US patients initiating CPAP (November 2015–October 2018), 72.6% met CMS adherence criteria, from 51.3% in women aged 18–30 to 80.6% in men aged 71–80 [8] [single-source]. In 42 PAP-naive veterans monitored for a year, 3-month CMS adherence predicted 1-year adherence with 65% sensitivity and 72% specificity, and 7 of 23 initially non-adherent patients later became adherent [9] [single-source]. Society statements have since called for removing the 4-hour rule and allowing telehealth for the follow-up visit (ATS 2023 [10]; CHEST/AARC/AASM/ATS panel 2021 [11]).
Transfers: A coverage condition that must be documented by the prescriber within a fixed early window, checked against objective device data, with denial as the consequence.
Does not transfer: The requirement follows prescription rather than preceding it; device-logged adherence makes documentation automatic in a way a failed exercise trial is not; the prescriber base is sleep medicine, not urogynecology or pelvic PT.
Had to show: Coverage in the home "if the patient has undergone a four-week trial of conservative therapy and the treating physician determines that there has been no significant improvement", the trial including "an appropriate compression bandage system or compression garment, exercise, and elevation of the limb", with documentation of "the treatments which have been tried and failed" (NCD 280.6, effective 2002-01-14) [12] [single-source]. The DME (durable medical equipment) MACs retired their local policy L33829 (a Medicare local coverage determination number) and article A52488 for dates of service on or after 2024-11-14, citing the existence of NCD 280.6 [13] [single-source].
What happened: In 26,902 commercially insured lymphedema patients (2012–2016), patients with phlebolymphedema and venous leg ulcer were 9.6% of the cohort, 7.8% of the conservative-care group and 17.7% of the device group, making up 23.5% of simple-device prescriptions [14] [single-source]. No retrieved study reports denial or audit rates tied to the four-week trial.
Transfers: A four-week conservative trial with named components, documented before a home device is prescribed, under the same payer program.
Does not transfer: The conservative trial is largely self-administered garments and elevation, not a supervised PT episode; the one prescribing-pattern study is commercial, where the Medicare trial rule does not necessarily apply.
Had to show: A trial rental "for a minimum of one month (30 days), but not to exceed two months", after which the practitioner determines whether long-term use justifies purchase (LCD (local coverage determination) L33802, effective 2024-01-01) [15] [single-source].
What happened: For chronic low back pain the trial pathway ended: NCD 160.27 (effective 2012-06-08) covers TENS for CLBP only within an approved clinical study [16] [single-source]. In 2017, 10 of 15 Medicaid plans covered TENS for low back pain, and utilisation management such as prior authorisation was common [18] [single-source]. No retrieved study measures prescribing before and after either policy.
Transfers: A documented home trial period gating purchase of a home electrical stimulator.
Does not transfer: The trial is with the device itself, not a failed alternative therapy; the indication is pain, and the CLBP outcome was an evidence-based non-coverage decision rather than a response to documentation burden.
Had to show: Medical necessity documentation from the clinical team, sent with the order for prior authorisation to a Medicare Administrative Contractor [19] [single-source].
What happened: One university clinic built an electronic transmission of the order and supporting documents from its EHR (electronic health record) to a MAC (Medicare administrative contractor) [19] [single-source]. Traditional Medicare power wheelchair vendors fell from over 1,292 to 986 between 2015 and 2022, and rural vendors from 374 to 182, a period of competitive bidding and prior authorisation [20] [single-source].
Transfers: A prescriber-side documentation burden answered with a template and workflow build.
Does not transfer: The study does not separate prior authorisation from competitive bidding; the documentation burden fell on suppliers as much as prescribers.
Had to show: No coverage condition; the case measures how an in-office income stream shaped episode intensity [21] [single-source].
What happened: Among Medicare total knee replacement patients (2007–2009), those treated at a physician-owned PT clinic received on average 8.3 more PT visits than patients of non-self-referring surgeons [21] [single-source].
Transfers: Prescribers whose practice earns from office-based therapy episodes, the incentive the experiment asks urogynecology practices with in-house pelvic PT to act against.
Does not transfer: Orthopaedic surgery, post-surgical rehabilitation, and no home-device alternative in the comparison.
[1] NCD 230.8 Non-Implantable Pelvic Floor Electrical Stimulator, version 2 — Centers for Medicare & Medicaid Services (published 2006-06-19, effective date; accessed 2026-09-30). NCD 230.8 — https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?ncdid=231 [payer-policy] [2] NCD 30.1.1 Biofeedback Therapy for the Treatment of Urinary Incontinence, version 1 — Centers for Medicare & Medicaid Services (published 2001-07-01, effective date; accessed 2026-09-30). NCD 30.1.1 — https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?ncdid=42 [payer-policy] [3] 21 CFR 876.5320 Nonimplanted electrical continence device — eCFR, issue 2026-09-25 via python3 -m connectors regulation (published 2026-09-25; accessed 2026-09-30). 21 CFR 876.5320 — https://www.ecfr.gov/current/title-21/section-876.5320 [federal-registry] [4] Product classification, product code KPI — FDA openFDA device/classification via python3 -m connectors classification (published date not given in the record; accessed 2026-09-30). product code KPI, 21 CFR 876.5320 — https://api.fda.gov/device/classification.json?search=product_code:KPI [federal-registry] [5] Barriers to pelvic floor physical therapy utilization for treatment of female urinary incontinence — American Journal of Obstetrics and Gynecology (published 2011-08, day not given in the PubMed record; accessed 2026-09-30). PMID (PubMed identifier) 21620356 — https://pubmed.ncbi.nlm.nih.gov/21620356/ [peer-reviewed] [6] Impact of social determinants of health on fecal incontinence treatment in older women — American Journal of Obstetrics and Gynecology (published 2025-12, day not given in the PubMed record; accessed 2026-09-30). PMID 40633708 — https://pubmed.ncbi.nlm.nih.gov/40633708/ [peer-reviewed] [7] LCD L33718 Positive Airway Pressure (PAP) Devices for the Treatment of Obstructive Sleep Apnea — DME MACs via CMS Medicare Coverage Database (published 2024-01-01, revision effective date; accessed 2026-09-30). LCD 33718 (L33718) — https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=33718 [payer-policy] [8] Age and Sex Disparities in Adherence to CPAP — Chest (published 2021-01, day not given in the PubMed record; accessed 2026-09-30). PMID 32687910 — https://pubmed.ncbi.nlm.nih.gov/32687910/ [peer-reviewed] [9] Centers for Medicare and Medicaid Services Positive Airway Pressure Adherence Criteria May Limit Treatment to Many Medicare Beneficiaries — Journal of Clinical Sleep Medicine (published 2019-02-15; accessed 2026-09-30). PMID 30736874 — https://pubmed.ncbi.nlm.nih.gov/30736874/ [peer-reviewed] [10] Moving toward Equitable Care for Sleep Apnea in the United States: Positive Airway Pressure Adherence Thresholds: An Official American Thoracic Society Policy Statement — American Journal of Respiratory and Critical Care Medicine (published 2023-02-01; accessed 2026-09-30). PMID 36722719 — https://pubmed.ncbi.nlm.nih.gov/36722719/ [guideline] [11] Optimal NIV (non-invasive ventilation) Medicare Access Promotion: Patients With OSA (obstructive sleep apnoea): A Technical Expert Panel Report — Chest (published 2021-11, day not given in the PubMed record; accessed 2026-09-30). PMID 34339689 — https://pubmed.ncbi.nlm.nih.gov/34339689/ [guideline] [12] NCD 280.6 Pneumatic Compression Devices, version 1 — Centers for Medicare & Medicaid Services (published 2002-01-14, effective date; accessed 2026-09-30). NCD 280.6 — https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?ncdid=225 [payer-policy] [13] Retirement of Pneumatic Compression Devices Local Coverage Determination (LCD) and Related Policy Article — Effective November 14, 2024 — Noridian JA DME (published 2024-10-03; accessed 2026-09-30). LCD 33829 (L33829); article A52488 — https://med.noridianmedicare.com/web/jadme/policies/dmd-articles/2024/retirement-of-pneumatic-compression-devices-local-coverage-determination-lcd-and-related-policy-article-effective-november-14-2024 [payer-policy] [14] Correlation of disease comorbidity with prescribed treatment among insured U.S. lymphedema patients — Journal of Vascular Surgery: Venous and Lymphatic Disorders (published 2021-03, day not given in the PubMed record; accessed 2026-09-30). PMID 32470618 — https://pubmed.ncbi.nlm.nih.gov/32470618/ [peer-reviewed] [15] LCD L33802 Transcutaneous Electrical Nerve Stimulators (TENS) — DME MACs via CMS Medicare Coverage Database (published 2024-01-01, revision effective date; accessed 2026-09-30). LCD 33802 (L33802) — https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=33802 [payer-policy] [16] NCD 160.27 Transcutaneous Electrical Nerve Stimulation (TENS) for Chronic Low Back Pain, version 1 — Centers for Medicare & Medicaid Services (published 2012-06-08, effective date; accessed 2026-09-30). NCD 160.27 — https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?ncdid=354 [payer-policy] [17] The national coverage decision for reimbursement for biofeedback and pelvic floor electrical stimulation for treatment of urinary incontinence — Journal of Wound, Ostomy and Continence Nursing (published 2002-01, day not given in the PubMed record; accessed 2026-09-30). PMID 11810068 — https://pubmed.ncbi.nlm.nih.gov/11810068/ [peer-reviewed] [18] Coverage of Nonpharmacologic Treatments for Low Back Pain Among US Public and Private Insurers — JAMA Network Open (published 2018-10-05; accessed 2026-09-30). PMID 30646222 — https://pubmed.ncbi.nlm.nih.gov/30646222/ [peer-reviewed] [19] Development of an Electronic Exchange of Medical Documentation for Power Mobility Devices — Applied Clinical Informatics (published 2021-03, day not given in the PubMed record; accessed 2026-09-30). PMID 33910261 — https://pubmed.ncbi.nlm.nih.gov/33910261/ [peer-reviewed] [20] Power wheelchair vendors: Declines in rural market activity — Disability and Health Journal (published 2026-10, issue month in the PubMed record, day not given; accessed 2026-09-30). PMID 42303535 — https://pubmed.ncbi.nlm.nih.gov/42303535/ [peer-reviewed] [21] Use of Physical Therapy Following Total Knee Replacement Surgery: Implications of Orthopedic Surgeons' Ownership of Physical Therapy Services — Health Services Research (published 2016-10, day not given in the PubMed record; accessed 2026-09-30). PMID 26913811 — https://pubmed.ncbi.nlm.nih.gov/26913811/ [peer-reviewed]
Well established: Only the device-class line: KPI as a Class II non-implanted electrical continence device rests on two federal records, openFDA classification [4] and eCFR [3]. Every coverage line rests on the one governing CMS document for it.
Thin: Every "What happened" line is [single-source] and, except the NCD texts, was read at PubMed-abstract depth only; no full text was opened. [8] uses one manufacturer's telemonitoring database (the abstract does not name it); the paper is peer-reviewed, so it is marked [single-source] rather than [manufacturer], but a reader should know the data origin. [9] is n=42. [14] is commercial, not Medicare. [20] does not separate prior authorisation from competitive bidding.
Rescoped from class 3: The row asks whether a documented-trial requirement would suppress prescribing, and whether clinicians earning from in-office episodes would refer patients home. Both are what people would do. Substituted twins: (a) measured adherence against a coverage threshold (CPAP [8][9]); (b) measured uptake of the conservative step that the documentation depends on (pelvic floor PT [5]); (c) observed prescribing mix under a trial rule (lymphedema [14]); (d) observed episode intensity when the prescriber owns the in-office service (PT after knee replacement [21]). None of these measures how a urogynecologist or pelvic floor PT would respond to a home-device option.
Out of scope: Commercial-payer PCD and pelvic-floor-device policies (several surfaced in search, not read); the HHS Departmental Appeals Board Medicare Appeals Council decision on a PCD supplier (fetch returned HTTP 403, not retrieved); CPT descriptors for biofeedback and PT codes; non-US coverage.
Not searched vs. not found:
hcpcs (E0651, E0601, E0720, E0740) and coverage returned no answer for want of local cache files data/hcpcs_level_ii.csv and data/medicare_coverage_policies.csv; ncd could not read the NCD manual (pypdf missing). Coverage text was instead read from the CMS Medicare Coverage Database documents themselves [1][2][7][12][15][16], and HCPCS (Healthcare Common Procedure Coding System) descriptors are not stated anywhere in this report.
[inference] The pelvic floor NCDs make the documented 4-week PME trial a precondition that is usually delivered by the office-based PT or biofeedback episode, so the same clinicians who document the failed trial are the ones whose episode the home device would replace. [inference]
[inference] CPAP's requirement became routine partly because the device produces the adherence record itself; a failed-exercise trial produces no such record unless the conservative step is also instrumented. [inference]
| Proposition | Evidence class | Resolvable identifier | Dossier section |
|---|---|---|---|
| Medicare NCD 230.8 covers a non-implantable pelvic floor electrical stimulator for stress and/or urge incontinence only after a documented failed trial of 4 weeks of ordered pelvic muscle exercise | 1 registry | NCD 230.8 | reimbursement |
| Medicare NCD 30.1.1 states that home use of biofeedback therapy for urinary incontinence is not covered | 1 registry | NCD 30.1.1 | reimbursement |
| FDA product code KPI is a Class II non-implanted electrical continence device under 21 CFR 876.5320 | 1 registry | 21 CFR 876.5320; product code KPI | reference-products |
| Medicare NCD 280.6 covers home pneumatic compression devices for lymphedema after a four-week trial of conservative therapy including compression, exercise and limb elevation | 1 registry | NCD 280.6 | reimbursement |
| DME MACs retired LCD L33829 and article A52488 for dates of service on or after 2024-11-14, citing NCD 280.6 | 1 registry | LCD L33829 | reimbursement |
| Among 789,260 US patients initiating CPAP (Nov 2015–Oct 2018), 72.6% met CMS adherence criteria | 2 published | PMID 32687910 | clinical-evidence |
| Among women referred to pelvic floor PT for urinary incontinence (2009–2010), 33% with private insurance did not participate, and insurance noncoverage was a risk factor for nonparticipation | 2 published | PMID 21620356 | care-pathway |
| Medicare total knee replacement patients treated at physician-owned PT clinics (2007–2009) received on average 8.3 more PT visits than patients of non-self-referring surgeons | 2 published | PMID 26913811 | care-pathway |
_shared/plain-language.md